BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-776.42	-535.76	-643.2	-481.18	-562.54	-448.72
Depreciation & Amortization	5.51	6.08	6.49	6.77	5.84	1.46
Loss (Gain) From Sale of Assets	-52.03	-178.32	1.24	6.26	-	-
Asset Writedown & Restructuring Costs	0.27	0.27	-	12.72	-	4.73
Loss (Gain) From Sale of Investments	-2.3	-8.14	-18.31	8.22	-29.91	-
Loss (Gain) on Equity Investments	59	31.18	-	-	-	-
Stock-Based Compensation	120.41	95.8	108.71	91.56	99.51	58.46
Other Operating Activities	75.69	36.12	12.29	-91.92	-6.43	-30.57
Change in Accounts Receivable	-76.21	-2.97	15.33	15.17	-19.75	-
Change in Accounts Payable	9.17	1.51	2.78	-0.35	2.83	-0.74
Change in Unearned Revenue	-6.85	21.88	-5.44	15.26	-	-
Change in Other Net Operating Assets	4.53	11.63	-7.61	-2	12.52	15.67
Operating Cash Flow	-655.81	-520.73	-527.72	-419.49	-497.93	-399.71
Capital Expenditures	-0.78	-0.93	-1.31	-4.82	-13.25	-7.52
Sale of Property, Plant & Equipment	-	-	-	10	-	-
Cash Acquisitions	-	-	-	-	13.65	-
Divestitures	-0.04	-0.14	-0.5	-	-	-
Sale (Purchase) of Intangibles	-10.88	-7.98	-	-1.5	-35	-
Investment in Securities	32.09	44.15	55.84	339.47	-166.23	-38.72
Other Investing Activities	-	25.68	-	110	-	-6.76
Investing Cash Flow	20.39	60.78	54.03	453.15	-200.83	-52.99
Long-Term Debt Issued	-	950	-	-	1,204	550
Long-Term Debt Repaid	-	-473.42	-	-20.49	-124.12	-
Net Debt Issued (Repaid)	916	476.58	-	-20.49	1,080	550
Issuance of Common Stock	17.92	322.9	459.22	8.08	20.46	14.13
Repurchase of Common Stock	-54.89	-7.53	-6.88	-1.56	-204.75	-75.71
Other Financing Activities	-42.01	-43.5	-0.8	0.84	-158.95	-41.23
Financing Cash Flow	837.01	748.46	451.54	-13.13	736.45	447.19
Net Cash Flow	201.59	288.51	-22.15	20.52	37.69	-5.52
Free Cash Flow	-656.59	-521.66	-529.03	-424.32	-511.18	-407.23
Free Cash Flow Margin	-278.44%	-235.08%	-5686.62%	-546.46%	-733.23%	-4936.74%
Free Cash Flow Per Share	-3.46	-2.80	-3.25	-2.88	-3.54	-3.45
Cash Interest Paid	65.57	91.34	61.11	54.44	29.77	15.32
Levered Free Cash Flow	-297.63	-288.27	-249.07	-285.88	-301.13	-250.16
Unlevered Free Cash Flow	-214.72	-226.21	-198.26	-235.61	-271.89	-227.25
Change in Working Capital	-85.94	32.04	5.06	28.08	-4.4	14.93

Updated Apr 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q